ANP
- Category
- Cardiovascular
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A naturally occurring 28-amino-acid hormone used in hospitals to rapidly offload a failing heart in acute heart failure, not marketed for wellness or longevity. Its blood-pressure and pulmonary-pressure-lowering effects are well established in humans, but easing breathlessness is only weakly supported, and it has never shown a mortality benefit. The main danger is hypotension. It is a regulated acute-care infusion, not a research-grade peptide.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Atrial Natriuretic Peptide (ANP) is a 28-amino-acid peptide hormone produced primarily by cardiomyocytes (heart muscle cells) in the atria of the heart. It is released in response to atrial stretch caused by increased blood volume or pressure, and it plays a critical role in regulating blood pressure, fluid balance, and sodium homeostasis. ANP acts by binding to natriuretic peptide receptor A (NPR-A), activating cyclic GMP (cGMP) signaling pathways that promote vasodilation, natriuresis (sodium excretion), and diuresis (water excretion), while suppressing the renin-angiotensin-aldosterone system (RAAS).
The clinical significance of ANP led to the development of nesiritide (Natrecor), a recombinant form of B-type natriuretic peptide (BNP, a closely related peptide also in the natriuretic peptide family) that was approved by the FDA in 2001 for the treatment of acutely decompensated congestive heart failure (CHF); FDA withdrew that approval in 2020. Nesiritide mimics the vasodilatory and diuretic effects of the endogenous natriuretic peptides, reducing pulmonary capillary wedge pressure and improving dyspnea in acute heart failure patients. ANP itself (as carperitide/Hanp) has been approved in Japan for acute heart failure since 1995.
Beyond heart failure, ANP and the natriuretic peptide system have been studied in hypertension, kidney disease, and metabolic regulation. BNP and NT-proBNP are used as biomarkers for heart failure diagnosis and prognosis; NT-proBNP is a B-type peptide precursor fragment, not a measurement of ANP. The natriuretic peptide pathway is now recognized as one of the most important neurohumoral systems in cardiovascular medicine, with decades of clinical validation.
How it works in the body
Atrial Natriuretic Peptide binds to natriuretic peptide receptor A (NPR-A), activating guanylate cyclase to produce cGMP. This causes vasodilation, promotes sodium and water excretion by the kidneys (natriuresis/diuresis), and inhibits the renin-angiotensin-aldosterone system, lowering blood pressure and reducing cardiac preload.
Research overview
The natriuretic peptide family (ANP, BNP, CNP) is among the most extensively studied peptide hormone systems in medicine. ANP was discovered in 1981 by Adolfo de Bold when atrial extracts were shown to produce dramatic natriuresis and diuresis. This landmark finding launched decades of research into natriuretic peptide biology. Nesiritide (recombinant BNP) was approved by the FDA in 2001 based on the VMAC trial (Vasodilation in the Management of Acute CHF, n=489) which showed significant reduction in pulmonary capillary wedge pressure vs. placebo and nitroglycerin. However, subsequent meta-analyses raised safety concerns about worsening renal function and mortality. The large ASCEND-HF trial (n=7141, NEJM 2011) found a small dyspnea difference that did not meet the prespecified significance threshold, with no reduction in mortality or rehospitalization at 30 days. Carperitide (recombinant ANP) has been used clinically in Japan since 1995. As of 2026, PubMed indexes over 30,000 publications on atrial natriuretic peptide, making it one of the most studied peptide hormones in existence.
Who researches ANP?
Commonly researched by
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
People researching respiratory health
Studied for effects on lung function, bronchial health, or respiratory tissue.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(4)
Rated by level of concern
Hypotension (dangerously low blood pressure)
HighPMID 11007679; PMID 26667591 (Circ J 2016, predictors of WRF on low-dose carperitide); PMID 26945407; Japanese carperitide package insert
Worsening renal function
ModeratePMID 26667591; PMID 9062091 (NEJM 1997); PMID 11007679; PMID 26945407
No mortality benefit despite hemodynamic effects
HighPMC12414238 (Cureus 2025 meta-analysis); PMC12751686 (BMC Cardiovasc Disord 2025 meta-analysis); PMID 26945407
Headache and nausea
LowPMID 26945407 (AE rates similar to placebo); carperitide/nesiritide label adverse reactions
Interaction summary(8)
Rated by direction with this peptide
Nitrates and other IV vasodilators (nitroglycerin, nitroprusside)
CautionModerateThere is no interaction study, only additive pharmacology. Both act through cGMP-mediated vasodilation, so co-infusion can be expected to compound hypotension - the dose-limiting effect of ANP - and both classes are contraindicated in symptomatic hypotension or cardiogenic shock. Continuous BP monitoring is warranted, but the additive-hypotension claim rests on mechanism and shared labelling, not on documented combination data.
Mechanistic/pharmacodynamic; carperitide and nitrate package insert contraindications; PMID 26945407 (hypotension profile)
PDE5 inhibitors (sildenafil, tadalafil)
CautionTheoreticalNo human study of ANP with a PDE5 inhibitor was identified. ANP raises cGMP production while PDE5 inhibitors block cGMP degradation, so the combination is predicted to potentiate vasodilation and hypotension by analogy with the documented nitrate/PDE5-inhibitor contraindication. Extrapolation, not evidence.
Mechanistic extrapolation; sildenafil label nitrate contraindication (shared cGMP pathway) - no ANP-specific data
Loop diuretics (furosemide)
SynergisticModerateComplementary decongestion - ANP adds natriuresis and preload reduction on top of loop diuresis and the two are routinely co-administered in Japanese practice - but the combination compounds volume depletion, hypotension and worsening renal function, and early poor diuretic response to carperitide predicts WRF and worse 1-year mortality/rehospitalization. Co-administration is observational practice, not a tested regimen.
PMC6005462 (PLoS One 2018); PMID 26667591
ACE inhibitors / ARBs
CautionModerateIn the cited study, enalapril did not restore renal responsiveness to ANP in congestive heart failure, indicating the resistance operates beyond RAAS activation. What remains is additive blood-pressure lowering and additive RAAS suppression, raising hypotension risk on initiation. This is mechanistic/additive rather than a documented drug-drug interaction.
PMID 2558792 (Cardiology 1989; shows ACEi does NOT restore ANP renal responsiveness); additive hypotension is mechanistic
Sacubitril/valsartan and other neprilysin inhibitors
CautionModerateNeprilysin is the main degradative enzyme for ANP, and in patients started on sacubitril/valsartan circulating ANP rapidly and substantially increased - more than doubling by the first follow-up. For exogenous ANP this is a pharmacokinetic amplification that raises hypotension risk as much as it raises effect, so the actionable direction is caution. It simultaneously distorts BNP-based monitoring (BNP rises or moves inconsistently while NT-proBNP, proBNP1-108 and MR-proANP fall).
PMID 30898202 (JACC 2019)
Non-oliguric acute tubular necrosis / critically ill patients with AKI
CautionModerateIn the 504-patient anaritide RCT there was no overall benefit (dialysis-free survival 43% vs 47%, P=0.35); the oliguric subgroup improved (27% vs 8%, P=0.008) while non-oliguric patients did WORSE (48% vs 59%, P=0.03), and the confirmatory trial in oliguric ARF was negative with 95% of treated patients dropping below 90 mm Hg systolic. ANP should not be used as a renal-protective agent in AKI. The evidence is subgroup-level, so it is rated Moderate rather than High.
PMID 9062091 (NEJM 1997); PMID 11007679 (Am J Kidney Dis 2000)
SGLT2 inhibitors and other volume-depleting agents
CautionTheoreticalOsmotic diuresis and natriuresis added to ANP-mediated natriuresis and vasodilation could plausibly amplify intravascular volume depletion and hypotension. No study of this combination was identified; this is extrapolation only.
Mechanistic extrapolation; no direct interaction study identified
Tolvaptan (vasopressin V2 antagonist)
NeutralLowThe AVCMA trial (J Clin Pharmacol 2013) randomized acute heart failure patients to tolvaptan VERSUS carperitide - it did not test the combination, so it is not evidence that co-administration is safe. It does show the agents act on distinct pathways (aquaresis vs natriuresis/vasodilation), with tolvaptan showing comparable efficacy and FEWER cardiovascular adverse events than carperitide. No pharmacological interaction has been demonstrated in either direction.
PMC4258069 (AVCMA trial, J Clin Pharmacol 2013; head-to-head comparison, not combination)
Known risks(4)
Hypotension (dangerously low blood pressure)
SeriousNesiritide can cause significant hypotension, especially at higher doses or in volume-depleted patients. The FDA label includes warnings about hypotension. Blood pressure monitoring is required during infusion.
Worsening renal function
Moderate (Debated)Early meta-analyses (Sackner-Bernstein 2005) raised concerns that nesiritide worsened renal function. The ASCEND-HF trial (2011) did not confirm this, showing no significant renal impairment vs. placebo. Risk remains debated.
No mortality benefit despite hemodynamic effects
Limitation (Not a Safety Risk)The ASCEND-HF trial demonstrated that despite hemodynamic improvements, nesiritide did not reduce 30-day mortality or rehospitalization. This limits its clinical utility relative to other heart failure treatments.
Headache and nausea
MildCommon side effects of nesiritide include headache, nausea, and dizziness, related to its vasodilatory effects.
Drug interactions(4)
ACE inhibitors and ARBs (enalapril, losartan, valsartan)
Additive hypotensive effect when combined with nesiritide. Both suppress RAAS and promote vasodilation. Enhanced risk of symptomatic hypotension; careful blood pressure monitoring required.
Loop diuretics (furosemide, bumetanide)
Additive diuretic and natriuretic effects may lead to excessive volume depletion, electrolyte imbalances, and hypotension. Electrolyte monitoring recommended.
Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)
Both PDE5 inhibitors and natriuretic peptides increase cGMP levels. Combined use may cause severe hypotension. Contraindicated or requires extreme caution.
Beta-blockers (metoprolol, carvedilol)
Additive blood-pressure-lowering effects. In acute heart failure, the combination may cause excessive hypotension and bradycardia. Hemodynamic monitoring required.
Research & benefits
Evidence base
- Evidence Level
- Moderate
- Total Studies
- 30000
- Human Participants
- 50000
ANP has human trial evidence and carperitide has been approved in Japan since 1995. A 477-patient rhANP trial found transient pulmonary-pressure improvement without significant dyspnea or mortality benefit. VMAC and ASCEND-HF studied BNP/nesiritide and provide related-peptide evidence, not direct ANP evidence: nesiritide was FDA-approved in 2001 on the VMAC trial, and the ASCEND-HF trial (n=7141) showed no mortality benefit. BNP and NT-proBNP levels are guideline-recommended biomarkers for heart failure diagnosis.
Researched for(6)
Rated by confidence in the evidence
Rapid reduction in pulmonary capillary wedge pressure in acute heart failure
HighPhase III RCT in 477 patients showed rapid drop in wedge pressure at 1 hour.
PMID 26945407 (rhANP phase III RCT, Medicine (Baltimore) 2016)
Improvement in dyspnea (breathlessness) in acutely decompensated CHF
SpeculativeLargest placebo-controlled RCT missed its dyspnea endpoint; symptom benefit remains unproven.
PMID 26945407 (primary endpoint negative)
Vasodilation and blood pressure reduction through cGMP-mediated smooth muscle relaxation
HighBlood pressure lowering is well documented in human RCTs; hypotension is the dose-limiting effect.
PMID 11007679 (randomized anaritide trial, Am J Kidney Dis 2000 - 95% with SBP <90 mm Hg on infusion); PMID 26945407
Natriuresis and diuresis — promotes sodium and water excretion to reduce volume overload
MediumIncreases sodium and water excretion in human studies, but response is often blunted in heart failure.
PMID 2821056 (human alpha-hANP infusion physiology, JCEM 1987); PMID 2558792 (blunted renal ANP response in CHF, Cardiology 1989); PMC6005462 (diuretic response to carperitide in ADHF, PLoS One 2018)
Suppression of renin-angiotensin-aldosterone system (RAAS) activation
MediumLowers renin and aldosterone in controlled human infusion studies; a hormonal effect, not a clinical outcome.
PMID 2948826 (Eur J Clin Pharmacol 1986); PMID 2821056 (JCEM 1987); PMID 2975458 (Am J Med 1988)
Diagnostic and prognostic biomarker value (NT-proBNP/BNP levels) for heart failure
MediumEstablished for BNP/NT-proBNP testing, though these reflect B-type peptides more than ANP itself.
PMID 30898202 (natriuretic peptide assays under neprilysin inhibition, JACC 2019); ACC/AHA/HFSA HF guideline natriuretic peptide recommendations (guideline consensus, not RCT)
Benefits(6)
Rapid reduction in pulmonary capillary wedge pressure in acute heart failure
Wang et al., Medicine 2016, PMID 26945407: randomized rhANP trial, 477 patients.
Improvement in dyspnea (breathlessness) in acute heart failure is unproven
Wang et al., Medicine 2016, PMID 26945407: the 477-patient placebo-controlled rhANP trial found no statistically significant dyspnea improvement. ASCEND-HF (nesiritide, a BNP drug; O'Connor et al., NEJM 2011, PMID 21732835, n=7141) is related-peptide evidence only.
Vasodilation and blood pressure reduction through cGMP-mediated smooth muscle relaxation
Multiple pharmacology studies; de Bold 1981 landmark discovery
Natriuresis and diuresis — promotes sodium and water excretion to reduce volume overload
Foundational natriuretic peptide physiology; Levin et al., NEJM 1998 review
Suppression of renin-angiotensin-aldosterone system (RAAS) activation
Multiple preclinical and clinical studies on natriuretic peptide/RAAS interaction
Diagnostic and prognostic biomarker value (NT-proBNP/BNP levels) for heart failure
ESC and AHA/ACC Heart Failure Guidelines; thousands of diagnostic studies
Key studies(4)
Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure (VMAC Trial)
Phase 3 RCTn=48924-48 hours acute treatmentPublication Committee for the VMAC Investigators
JAMA
2002
Nesiritide significantly reduced pulmonary capillary wedge pressure compared to placebo (-5.8 mmHg vs -2.0 mmHg at 3 hours) and improved dyspnea compared to placebo at 3 hours. Led to FDA approval of nesiritide for acute CHF.
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure (ASCEND-HF)
Phase 3 RCTn=714130 days follow-upO'Connor CM, Starling RC, Hernandez AF, et al.
New England Journal of Medicine
2011
Nesiritide was not associated with an increase or decrease in death or rehospitalization at 30 days. There was a small, non-significant improvement in dyspnea. Nesiritide did not worsen renal function, contradicting earlier meta-analyses.
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
Landmark DiscoveryPreclinicalde Bold AJ, Borenstein HB, Veress AT, Sonnenberg H
Life Sciences
1981
Landmark discovery that atrial extracts contain a potent natriuretic and diuretic substance, establishing the heart as an endocrine organ. This discovery launched the entire field of natriuretic peptide research.
Natriuretic Peptides
ReviewLevin ER, Gardner DG, Samson WK
New England Journal of Medicine
1998
Comprehensive review of natriuretic peptide biology and clinical applications in heart failure. Established the role of ANP and BNP as key regulators of cardiovascular homeostasis and their potential as therapeutic targets.
Regulation & availability
Why researchers look at it
ANP and the natriuretic peptide system represent one of the most important hormonal pathways in cardiovascular medicine, with FDA-approved drugs (nesiritide, sacubitril/ valsartan) and universally used biomarkers (NT-proBNP) for heart failure. Understanding this pathway is essential for anyone interested in cardiovascular health, fluid balance, and the heart's role as an endocrine organ.
- Estimated cost
- Not available as a consumer product — nesiritide (Natrecor) is hospital IV only
- FDA status
- ANP/carperitide is not FDA-approved. The related drug nesiritide is recombinant BNP. Natrecor was approved on August 10, 2001 for specified acute decompensated heart failure, but FDA withdrew its approval effective June 15, 2020 after the sponsor stopped marketing it. Its use had declined after the 2011 ASCEND-HF trial showed no mortality benefit.
- WADA status
- ANP, BNP, and nesiritide are not individually named in the 2026 WADA Prohibited List. Name absence does not establish permission: S5 prohibits diuretics and substances with similar biological effects. A substance-specific determination should be obtained before athletic use.
- Prescribability
- ANP/carperitide has no identified FDA approval. Carperitide is a prescription acute-heart-failure medicine in Japan. Nesiritide is BNP, and Natrecor's US approval was withdrawn in 2020.
- Availability
- Carperitide, recombinant ANP marketed as Hanp, is authorized in Japan for intravenous treatment of acute heart failure. ANP as a standalone peptide is not commercially available for therapeutic use outside this formulation. Nesiritide is the separate BNP peptide; Natrecor was discontinued and its US approval withdrawn in 2020, after its use declined when the ASCEND-HF trial showed no mortality benefit. NT-proBNP and BNP diagnostic assays are widely available in clinical laboratories worldwide.
International status
EU
Not approved (nesiritide withdrawn from EU consideration)
US
ANP/carperitide is not FDA-approved. Nesiritide is BNP; Natrecor's approval was withdrawn in 2020.
Japan
Approved as carperitide (Hanp) since 1995
Worldwide
Hospital use only — IV administration
Regulatory timeline(10)
- 1981Adolfo de Bold and colleagues report a rapid natriuretic response to rat atrial extracts in Life Sciences.
- 1984ANP amino acid sequence determined; structure of the 28-amino-acid peptide elucidated
- 1988BNP (B-type natriuretic peptide) discovered in porcine brain extracts by Sudoh et al.
- 1995Carperitide (recombinant ANP, Hanp) approved in Japan for acute heart failure
- 2001-08FDA approves nesiritide (Natrecor, recombinant BNP) for acute decompensated CHF
- 2002VMAC trial published in JAMA confirming hemodynamic benefits of nesiritide
- 2005Safety concerns raised by Sackner-Bernstein meta-analysis (renal function, mortality)
- 2011ASCEND-HF trial (n=7141) published in NEJM — no mortality benefit, safety profile acceptable
- 2014The pivotal Phase 3 PARADIGM-HF results for sacubitril/valsartan are published in the New England Journal of Medicine.
- 2015FDA approves sacubitril/valsartan (Entresto) for heart failure — validating natriuretic peptide pathway
Sources & FAQs
Research sources(6)
- VMAC Trial — Nesiritide vs Nitroglycerin in Acute CHF (JAMA 2002)
- ASCEND-HF Trial — O'Connor et al. (NEJM 2011)
- de Bold AJ et al. — Landmark ANP Discovery (Life Sciences 1981)
- Mathur AG et al. — Nesiritide Review (MJAFI 2005)
- Yancy CW et al. — The Tumultuous Journey of Nesiritide (Circ Heart Fail 2008)
- FDA — Natrecor (nesiritide) Prescribing Information
Frequently asked questions(4)
What is the difference between ANP and BNP?
ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide) are both members of the natriuretic peptide family with similar biological effects. ANP is primarily produced in the atria; BNP is produced mainly in the ventricles. Both promote vasodilation, natriuresis, and diuresis. Nesiritide is recombinant BNP. ANP and BNP have diagnostic value in heart failure. NT-proBNP is a B-type peptide precursor fragment and does not measure ANP.
Is nesiritide still used in clinical practice?
Nesiritide use has declined substantially since the 2011 ASCEND-HF trial showed no mortality benefit in acute heart failure. Natrecor was discontinued, and FDA withdrew its approval effective June 15, 2020. Most heart failure guidelines do not recommend it as first-line therapy; other vasodilators and diuretics are generally preferred.
Can ANP be used for high blood pressure?
ANP has potent blood-pressure-lowering effects through vasodilation and natriuresis. However, its short half-life (2-5 minutes) and requirement for IV administration make it impractical for chronic hypertension treatment. Research into oral neprilysin inhibitors (like sacubitril, which prevents ANP breakdown) has been more successful for chronic cardiovascular conditions.
What do ANP and BNP blood tests measure?
BNP and NT-proBNP blood tests measure circulating levels of natriuretic peptides released by the heart in response to increased wall stress. Elevated levels indicate the heart is under strain and are used to diagnose and monitor heart failure. These are among the most important blood tests in modern cardiology, recommended by all major heart failure guidelines.